SUMMARY A prospective study over one year of patients who had active rheumatoid arthritis discovered 64 who had received treatment for an adequate time with second-line drugs. In these patients there was evidence of continuing joint destruction as shown by radiological progression. During the year there were highly significant correlations between improvements in clinical and laboratory measurements, but neither group of tests was related to the degree of radiological change. However, in the second 6 months of treatment there was evidence that radiological progression was reduced. In a second prospective study of 88 patients with rheumatoid arthritis given prolonged, intensive therapy with second-line drugs and followed up for 10 years two-thirds showed radiological progression. However, the number of joints damaged per year fell significantly during the study period. There was a divergence between deterioration in radiological features and improvements in the ESR and functional capacity, though patients with a persistently low ESR had less radiological progression. These studies provide evidence that treatment may be associated with a reduced rate of radiological progression but suggest that changes in radiological progression and clinical and laboratory measurements may result from different mechanisms.
A variety of radiological changes occur in rheumatoid arthritis (RA) . They include osteoporosis, bone erosions, loss of cartilage, subluxation, and secondary osteoarthritis.' Active RA is characterised by radiological evidence of progressive joint damage, and if this radiological progression is reduced or prevented it may indicate control of the disease process.2`4 A variety of methods have been devised to assess radiological changes in RA which can be used to study their progression. 5`8 Drugs such as gold and penicillamine form an identifiable group of agents in RA, often termed 'secondline' or 'disease-modifying' drugs. They reduce not only the inflammatory synovitis but also the erythrocyte sedimentation rate (ESR) and the levels of acute-phase proteins such as C-reactive protein. 9'14 These effects are not immediate but occur after a delay of weeks or months. Corticosteroids may also influence the acute-phase response, though their effects occur more rapidly. "5 Accepted for publication 14 Controlled studies of second-line drugs in RA have clearly shown that they decrease joint inflammation and the acute-phase response in companson with placebos.-6-21 Moreover, Amos et al.22 showed that patients in a steady state with persistently low ESRs and C-reactive protein levels had only minimal evidence of radiological progression compared with those patients in whom these indicators of the acutephase response stayed high. But many of the major placebo-controlled trials of drugs such as gold and penicillamine have failed to show any effect on radiological progression, despite significant reductions in the acute synovitis and acute-phase response. Thus, despite advances in understanding RA, the relationship of radiological changes to both clinical and laboratory features of the disease has not been completely elucidated.
Our objective was to refine the current concepts on the interrelationships between radiological changes and clinical and laboratory variables in RA, especially with respect to treatment with second-line drugs. We have done this in 2 complementary studies; one short-term (over one year) and one long-term (over 10 years).
SHORT-TERM STUDY
Sixty-four patients with definite or classical RA (American Rheumatism Association criteria) were studied. They were selected from those entered into 2 prospective studies of second-line drugs in active RA. There were originally 102 patients in the studies; all had active disease with more than 1 hour of morning stiffness, 3 or more swollen tender joints, and a raised ESR (>30 mm/h). Only those followed prospectively for one year who had an adequate and continuous course of second-line drugs for at least 8 months were included in this study; of the 64 patients 44 were female and 20 male; their mean age was 47 years (range 19-76). They had had RA for a mean of 6 years (SD 6); 14 All patients had similar intensive therapy. This included bed rest in the early stages and physiotherapy. They all received second-line drugs and/or steroids (only 5 patients received steroids alone). These were given over prolonged periods with the aim of suppressing disease activity as completely as possible. They were withdrawn only because of serious adverse reactions, lack of effect, or if a patient entered a prolonged remission. If one second-line drug was withdrawn and the patient was not in remission, another was started. In cases failing to respond these drugs were used in combination. Patients were seen regularly (in general at least every 6 months); if there was any indication of marked activity they were readmitted to hospital. They received the following second-line drugs for 3 The relative rate of radiological progression was also assessed. The number of joints damaged at the start of the study was related to the duration of RA (in years) to give an 'initial' (prestudy) rate of radiological progression expressed as joints damaged per year. The number of joints damaged during the 10-year period of study was then related to the exact follow-up period (in years) to give the rate of radiological progression during the study expressed as joints damaged per year. In both instances the 0-22 point grading system described above was used to determine the number of damaged joints.
Of the 112 patients entering the study 1 died before 5 years. By 10 years a further 16 patients had died, 5 had moved away from Droitwich and for 2 the x-rays were not available; 88 patients were therefore available for follow-up at 10 years.
Results

SHORT-TERM STUDY
Radiological changes during the 12 months of this study, assessed by the Larsen index, are shown in Fig.  1 . Radiological progression occurred in 57 patients (89%); at best patients showed no significant deterioration. The majority of patients did not initially have severe joint destruction; the mean Larsen score at the beginning of the study was 45-4. The mean change was an increase of 8-9 (20% of initial value); the maximum was an increase of 34 (380% of initial value) during the year. Progression was equally likely in those with minimal radiological evidence of joint damage at the beginning of treatment as in those whose initial joint damage was severe.
The x-ray changes can be contrasted with those seen in the ESR (Fig. 2) with the greatest radiological changes and those with the least change (Table 4 ). In these patients there can be no question of difficulties in determining their radiological grouping. However, the 2 groups showed similar changes in clinical and laboratory measurements, which is further evidence for the divergence of radiological changes in this short assessment over a period of rapid change. It would be expected from previous studies and the preceding results that disease duration would be a major factor determining the extent of joint damage in patients with severe disease. Table 5 shows that there was a highly significant correlation between the initial Larsen score and disease duration. There was also some evidence, in our highly selected group of patients, that the initial Larsen score might be related to the initial disease activity; and this had a weak association with immunoglobulin levels and grip strength ( An analysis of radiological changes in relation to the initial degree of joint damage is shown in Table 6 . This indicates that a considerable proportion of change is due to radiological damage of joints which, at the beginning of the study, were normal or only slightly involved. It suggests that there is a general deterioration, involving all degrees of damage.
In 22 patients the x-rays at 6 months were evaluated in addition to those at 0 and 12 months. There was some evidence that the rate of progression had slowed during the 6-12 month period. In these x-rays the mean initial Larsen score was 33-9 (SEM 3-9); the 6-month value 39.1 (SEM 4.0), and the 12-month value 41-4 (SEM 3-6). Thus 69% of the total change occurred in the first 6 months and only 31% in the period 6-12 months. We also analysed the effect of a low ESR in the second 6 months of the study. Patients with an ESR at both 6 and 12 months of 25 mnmh or less were compared with other patients. They had less radiological progression. The patients with the low ESRs had, over the 12 months, a mean change in Larsen score of 7-5 (SEM 1-52, n=32); those with higher ESRs had a mean change in Larsen score of 10-7 (SEM 1-70, n=32). These differences were not significant at the 5 %level, but they were compatible with the view that a reduced ESR is associated with less radiological deterioration.
LONG-TERM STUDY
The divergence between the laboratory and radiological changes seen in the short-term study was also seen in the long-term study by the somewhat different method of radiological assessment of a modified Steinbroker grading. Thus, while there were improvements in the ESR, functional capacity, and Rose-Waaler titre in many patients at 5 and 10 years, there was a considerable deterioration in the radiological changes. This is summarised for grouped results in Table 7 .
There was some evidence that treatment was associated with a reduced rate of x-ray progression. The rate of loss of joints prior to treatment was significantly greater than that during the 10-year period of the study. The mean initial rate of loss was 1-37 joints damaged per year (SD 1-96); the rate of loss during the study was 0-53 joints damaged per year (SD 0-56), a highly significant reduction (p<0-001). This is shown in Fig. 3 .
Patients who had a low ESR had considerably less radiological progression than those with a persistently high ESR (Table 8) . though only a small number of patients fell into the latter group. Comparing the extent of radiological progression at 5 years in patients with a persistently low ESR (less than 20 mm/h) with that of all other patients showed that these had significantly less progression (p<0-05), as shown in Table 9 .
In the short-term study we showed that at a point in Rate during study period Fig. 3 Long-term study. Rate of radiological progression: initial (prestudy) rate and rate during study period shown. The means for each group are shown by horizontal bars. There was a significant reduction in the rate ofjoint damage (p<00) time the extent of radiological damage was related to disease duration. We have therefore examined whether, in the long term, x-ray progression is also influenced by disease duration. But we found no evidence of this (Table 10) . changes in rheumatoid arthritis. 
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